{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:53:02Z","timestamp":1783947182493,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Given the importance of inflammation at the onset of multiple sclerosis (MS), therapy is mainly based on the use of anti-inflammatory drugs including disease modifying therapies (DMTs). Considering the recent approval of some DMTs, pharmacovigilance becomes a fundamental tool for the acquisition of new safety data. The aim of the study was to analyze adverse drug reactions (ADRs) related to the use of drugs approved for MS. All national publicly-available aggregated ADR reports recorded from 2002 to 2020 into the Reports of Adverse Reactions of Medicines (RAM) system and all complete Sicilian data reported into the Italian spontaneous reporting system (SRS) database having as suspected drugs interferon \u03b2-1a (IFN \u03b2-1a), interferon \u03b2-1b (IFN \u03b2-1b), peginterferon \u03b2-1a (PEG-IFN \u03b2-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected. Descriptive analyses of national, publicly-available aggregated data and full-access regional data were performed to assess demographic characteristics and drug-related variables followed by a more in-depth analysis of all Sicilian ADRs with a case-by-case assessment and a disproportionality analysis of unexpected ADRs. A total of 13,880 national reports have been collected from 2002 to 2020: they were mainly not serious ADRs (67.9% vs. 26.1%) and related to females (71.7% <jats:italic>vs.<\/jats:italic> 26.3%) in the age group 18\u201365\u00a0years (76.5%). The most reported ADRs were general and administration site conditions (<jats:italic>n<\/jats:italic> = 6,565; 47.3%), followed by nervous (<jats:italic>n<\/jats:italic> = 3,090; 22.3%), skin (<jats:italic>n<\/jats:italic> = 2,763; 19.9%) and blood disorders (<jats:italic>n<\/jats:italic> = 2,180; 15.7%). Some unexpected Sicilian ADRs were shown, including dyslipidemia for FNG (<jats:italic>n<\/jats:italic> = 10; ROR 28.5, CI 14.3\u201359.6), NTZ (<jats:italic>n<\/jats:italic> = 5; 10.3, 4.1\u201325.8), and IFN \u03b2-1a (<jats:italic>n<\/jats:italic> = 4; 8.7, 3.1\u201324.1), abortion and alopecia for NTZ (<jats:italic>n<\/jats:italic> = 9; 208.1, 73.4\u2013590.1; <jats:italic>n<\/jats:italic> = 3; 4.9, 1.5\u201315.7), and vitamin D deficiency for GA (<jats:italic>n<\/jats:italic> = 3; 121.2, 30.9\u2013475.3). Moreover, breast cancer with DMF (<jats:italic>n<\/jats:italic> = 4, 62.8, 20.5\u2013191.9) and hypothyroidism with Cladr (<jats:italic>n<\/jats:italic> = 3; 89.2, 25.9\u2013307.5) were also unexpected. The reporting of drugs-related ADRs in MS were mostly reported in the literature, but some unknown ADRs were also found. However, further studies are necessary to increase the awareness about the safety profiles of new drugs on the market.<\/jats:p>","DOI":"10.3389\/fphar.2022.808370","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:42:01Z","timestamp":1645620121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database"],"prefix":"10.3389","volume":"13","author":[{"given":"Maria Antonietta","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Elisa","family":"Sorbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cicala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Maria","family":"Cutroneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/1352458519855725","article-title":"Acute Cardiotoxicity Associated with Alemtuzumab Infusion for Multiple Sclerosis","volume":"26","author":"Ahrabian","year":"2020","journal-title":"Mult. Scler."},{"key":"B2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awy006","article-title":"The Value of Oligoclonal Bands in the Multiple Sclerosis Diagnostic Criteria","volume":"141","author":"Arrambide","year":"2018","journal-title":"Brain"},{"key":"B4","first-page":"3126","article-title":"Patterns of Local Site Reactions to Subcutaneous Glatiramer Acetate Treatment of Multiple Sclerosis: a Clinicopathological Study","volume":"11","author":"Aviv","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential Mechanisms of Action Related to the Efficacy and Safety of Cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/jcpt.13391","article-title":"Adverse Drug Reactions with Oral Anticoagulants: Data from Sicilian Spontaneous Reporting System Database","volume":"46","author":"Barbieri","year":"","journal-title":"J. Clin. Pharm. Ther."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00278-z","article-title":"Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database","author":"Barbieri","year":"","journal-title":"Drugs - Real World Outcomes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia Is Not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term Safety and Effectiveness of Natalizumab Treatment in Clinical Practice: 10 Years of Real-World Data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and Efficacy of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis (FREEDOMS II): a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.3390\/ijms21082950","article-title":"Multiple Sclerosis Treatment and Melanoma Development","volume":"21","author":"Carbone","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in Multiple Sclerosis: Long-Term Management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple Sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s13311-021-01073-y","article-title":"Association between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis","volume":"18","author":"Dolladille","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B15","unstructured":"New Recommendations to Minimise Risks of the Rare Brain Infection PML and a Type of Skin Cancer with Gilenya2015"},{"key":"B16","unstructured":"PRAC Recommendations on Signals2017"},{"key":"B17","unstructured":"Updated Restrictions for Gilenya: Multiple Sclerosis Medicine Not to Be Used in Pregnancy"},{"key":"B18","unstructured":"Use of Multiple Sclerosis Medicine Lemtrada Restricted while EMA Review Is Ongoing"},{"key":"B19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple Sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1124\/jpet.103.062828","article-title":"Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes","volume":"309","author":"Forrest","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s40264-018-0782-8","article-title":"Managing Risks with Immune Therapies in Multiple Sclerosis","volume":"42","author":"F\u00f6rster","year":"2019","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying Treatments for Early and Advanced Multiple Sclerosis: a New Treatment Paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.15586\/codon.multiplesclerosis.2017.ch2","article-title":"Living with Multiple Sclerosis in Europe: Pharmacological Treatments, Cost of Illness, and Health-Related Quality of Life across Countries","volume-title":"MULTIPLE SCLEROSIS Perspectives In Treatment And Pathogenesis","author":"Gitto","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/DDDT.S137572","article-title":"Comparison of Efficacy and Safety of Oral Agents for the Treatment of Relapsing-Remitting Multiple Sclerosis","volume":"11","author":"Guarnera","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"s159","DOI":"10.1177\/1352458515591862","article-title":"Current and Emerging Treatment of Multiple Sclerosis","volume":"22","author":"Hart","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","article-title":"Cladribine: Mechanisms and Mysteries in Multiple Sclerosis","volume":"89","author":"Jacobs","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","article-title":"Dimethyl Fumarate Inhibits the Nuclear Factor \u03baB Pathway in Breast Cancer Cells by Covalent Modification of P65 Protein","volume":"291","author":"Kastrati","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1212\/WNL.0000000000004716","article-title":"Comorbidity Increases the Risk of Relapse in Multiple Sclerosis: A Prospective Study","volume":"89","author":"Kowalec","year":"2017","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009333.pub3","article-title":"Interferons-beta versus Glatiramer Acetate for Relapsing-Remitting Multiple Sclerosis","volume":"2016","author":"La Mantia","year":"20162016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40120-020-00204-5","article-title":"Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma under Cladribine Treatment","volume":"9","author":"Lebrun-Frenay","year":"2020","journal-title":"Neurol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102572","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term Safety Data from the Cladribine Tablets Clinical Development Program in Multiple Sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative Efficacy and Acceptability of Disease-Modifying Therapies in Patients with Relapsing-Remitting Multiple Sclerosis: a Systematic Review and Network Meta-Analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","article-title":"The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review","volume":"10","author":"Ma","year":"2019","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A Systematic Review of the Incidence and Prevalence of Comorbidity in Multiple Sclerosis: Overview","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"B38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/09546634.2018.1467539","article-title":"Interferon-beta Injection Site Reactions in Patients with Multiple Sclerosis","volume":"29","author":"Maurelli","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A Method for Estimating the Probability of Adverse Drug Reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1352458512473189","article-title":"Dendritic Cells in Multiple Sclerosis: Key Players in the Immunopathogenesis, Key Players for New Cellular Immunotherapies?","volume":"19","author":"Nuyts","year":"2013","journal-title":"Mult. Scler."},{"key":"B41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","article-title":"WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems","volume":"36","author":"Pal","year":"2013","journal-title":"Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and Obstacles of the Spontaneous Adverse Drugs Reactions Reporting: Two \u201cChallenging\u201d Case Reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The Sequence of Disease-Modifying Therapies in Relapsing Multiple Sclerosis: Safety and Immunologic Considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1126\/science.aav7188","article-title":"Multiple Sclerosis Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility","volume":"365","author":"Patsopoulos","year":"2019","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12944-020-01221-x","article-title":"Lipoprotein Profiling in Early Multiple Sclerosis Patients: Effect of Chronic Inflammation?","volume":"19","author":"R\u00e1dikov\u00e1","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.79986","article-title":"Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety","author":"Raschi","year":"2019","journal-title":"Pharmacovigilance"},{"key":"B47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11481-020-09937-4","article-title":"Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients","volume":"15","author":"Rauma","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1446944","article-title":"Managing the Side Effects of Multiple Sclerosis Therapy: Pharmacotherapy Options for Patients","volume":"19","author":"Rommer","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1212\/WNL.0b013e3181a92b96","article-title":"Effect of Statins on Clinical and Molecular Responses to Intramuscular Interferon Beta-1a","volume":"72","author":"Rudick","year":"2009","journal-title":"Neurology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/med.21567","article-title":"Dimethyl Fumarate, a Two-Edged Drug: Current Status and Future Directions","volume":"39","author":"Saidu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-019-01135-8","article-title":"Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","article-title":"Vitamin D and Multiple Sclerosis: A Comprehensive Review","volume":"7","author":"Sintzel","year":"2018","journal-title":"Neurol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7224\/1537-2073-14.1.46","article-title":"Injectable Multiple Sclerosis Medications: A Patient Survey of Factors Associated with Injection-Site Reactions","volume":"14","author":"Stewart","year":"2012","journal-title":"Int. J. MS Care"},{"key":"B54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: A Review in Multiple Sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2014.10.020","article-title":"Vascular Comorbidities in the Onset and Progression of Multiple Sclerosis","volume":"347","author":"Tettey","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B56","first-page":"1","volume-title":"Atlas of MS 3 Rd Edition","year":"2020"},{"key":"B57","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.msard.2019.101866","article-title":"Two Cases of Meningitis Associated with Ocrelizumab Therapy","volume":"38","author":"Theriault","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of Multiple Sclerosis - success from Bench to Bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10072-019-03772-z","article-title":"Correction to: The Italian Multiple Sclerosis Register","volume":"40","author":"Trojano","year":"2019","journal-title":"Neurol. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/cpt.207","article-title":"Drug-induced Progressive Multifocal Leukoencephalopathy: Lessons Learned from Contrasting Natalizumab and Rituximab","volume":"98","author":"Vermeer","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.msard.2019.01.019","article-title":"Single-arm Study to Assess Comprehensive Infusion Guidance for the Prevention and Management of the Infusion Associated Reactions (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Alemtuzumab (EMERALD)","volume":"29","author":"Vukusic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1002685","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and Risk of Infection and Infection-Related Death in 98,344 Individuals from a Prospective Danish Population-Based Study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0038-1649502","article-title":"Multiple Sclerosis","volume":"38","author":"Yamout","year":"2018","journal-title":"Semin. Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.808370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:42:12Z","timestamp":1645620132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.808370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":63,"alternative-id":["10.3389\/fphar.2022.808370"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.808370","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"article-number":"808370"}}